drug
fostamatinib disodium
Marketedupdated 3mo agoby $RIGL RIGEL PHARMACEUTICALS INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying fostamatinib disodium
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 6, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (28)
- Jul 27, 2032formulationUS 8771648
- Jul 27, 2032formulationUS 8771648
- Jul 27, 2032method-of-use (U-2294)US 8951504
- Jul 27, 2032method-of-use (U-2294)US 8951504
- Sep 4, 2031compositionUS 7449458
- Sep 4, 2031compositionUS 7449458
- Nov 24, 2030formulationUS 82631224.3y
- Nov 24, 2030formulationUS 82631224.3y
- Nov 6, 2028formulationUS 86524922.2y
- Nov 6, 2028formulationUS 86524922.2y
- Jun 17, 2026compositionUS 8163902
- Jun 17, 2026compositionUS 8163902
- Jun 17, 2026formulationUS 8445485
- Jun 17, 2026formulationUS 8445485
- Jun 17, 2026method-of-use (U-2294)US 8912170
- Jun 17, 2026method-of-use (U-2294)US 8912170
- Jun 17, 2026method-of-use (U-2294)US 9283238
- Jun 17, 2026method-of-use (U-2294)US 9283238
- Jun 12, 2026compositionUS 7989448
- Jun 12, 2026compositionUS 7989448
- Mar 28, 2026compositionUS 7538108
- Mar 28, 2026compositionUS 7538108
- Jan 19, 2026compositionUS 8211889
- Jan 19, 2026compositionUS 8211889
- Jan 19, 2026method-of-use (U-2294)US 9266912
- Jan 19, 2026method-of-use (U-2294)US 9266912
- Jan 19, 2026formulationUS RE48898
- Jan 19, 2026formulationUS RE48898
News(1)
- Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugA deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.biopharma_dive · 3mo ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that